MediWound Ltd. filed a free writing prospectus on November 3, 2026, announcing a $15 million bought deal public offering of 1,200,000 ordinary shares at $12.50 per share, with closing expected on or about November 5, 2026.

Key Highlights

  • Offering size: 1,200,000 ordinary shares priced at $12.50 per share to the public.
  • Gross proceeds: Expected to be approximately $15 million, before underwriting discounts, commissions, and offering expenses, assuming no exercise of the overallotment option.
  • Overallotment option: MediWound has granted the underwriter a 30-day option to purchase up to an additional 180,000 ordinary shares at the public offering price.
  • Sole book-runner: H.C. Wainwright and Co., LLC is acting as the sole book-running manager under a firm commitment underwriting agreement.
  • Use of proceeds: MediWound intends to use the net proceeds for working capital and general corporate purposes.
  • Registration basis: The shares are offered under a shelf registration statement on Form F-3 (File No. 333-285908), originally filed March 19, 2025 and declared effective March 27, 2025.

MediWound's Firm Commitment Offering Terms and Structure

According to the filing, MediWound Ltd. (NASDAQ:MDWD) entered into an underwriting agreement with H.C. Wainwright and Co., LLC, under which the underwriter has agreed to purchase on a firm commitment basis 1,200,000 ordinary shares at a price of $12.50 per ordinary share to the public, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about November 5, 2026, subject to satisfaction of customary closing conditions, the filing disclosed.

The company also granted the underwriter a 30-day option to purchase up to an additional 180,000 ordinary shares at the public offering price, less underwriting discounts and commissions. The filing states that gross proceeds are expected to be approximately $15 million before deducting underwriting discounts, commissions, and offering expenses, and assume no exercise of that option. MediWound disclosed that net proceeds are intended for working capital and general corporate purposes.

The ordinary shares are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-285908), which was originally filed with the SEC on March 19, 2025, and declared effective by the SEC on March 27, 2025, according to the filing. The filing references MediWound's FDA-approved biologic NexoBrid, indicated for enzymatic removal of eschar in thermal burns, and its investigational candidate EscharEx for the debridement of chronic wounds. The filing contains forward-looking statements, which MediWound cautioned are subject to risks and uncertainties and may differ materially from actual results.

What Was Disclosed

MediWound filed a free writing prospectus disclosing a $15 million bought deal offering of 1,200,000 ordinary shares at $12.50 each, with H.C. Wainwright and Co. as sole book-runner, an overallotment option for 180,000 additional shares, and an expected closing around November 5, 2026.